Anixa Biosciences Inc (NASDAQ:ANIX)
| Market Cap | $93.17M-39.0% |
| Revenue (ttm) | $0 |
| Net Income | -$10.42M+6.2% |
| EPS | -$0.30-777.8% |
| Shares Out | 34.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 276,085 |
| Open | $2.72 |
| Previous Close | $2.78 |
| Day's Range | $2.66 - $2.85 |
| 52-Week Range | $2.32 - $5.46 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | $6.00(+123.88%) |
| Earnings Date | Jan 11, 2027 |
About ANIX
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Anixa Biosciences Inc Stock Analysis — InsiderScore
Anixa Biosciences Inc scored higher than 93% of companies evaluated by InsiderBuying, and ranked 5th out of 94 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Anixa Biosciences Inc bought $291.6K of stock across 10 purchases in the last 90 days, the largest of them $131.9K.
The average purchase added about 2% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ANIX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Jan 11, 2027Earnings report
$ANIX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANIX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANIX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANIX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ANIX Revenue by Segment or Geography
As of: Q3 2026 (Jul 31, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ANIX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANIX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ANIX
| VTIVanguard Morningstar Total Stock Market ETF | $2.75M |
| VXFVanguard Extended Market ETF | $1.04M |
| IWCiShares Micro-Cap ETF | $271.32K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ANIX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+39.1 since Sep 12Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.